Background: Platelet-derived growth factors (PDGFs) and vascular endothelial growth factors and their receptors [platelet-derived growth factor receptors (PDGFRs) and vascular endothelial growth factor receptors (VEGFRs)] are related to both angiogenesis and lymphangiogenesis and are important targets in new cancer treatment strategies. We aimed to study the PDGFs/PDGFRs and correlations with lymph node metastasis (LNM) and investigate the prognostic impact of the co-expression of PDGF-B and VEGFR-3 and its correlation with LNM. Results: There were 232 N0 and 103 N+ patients (76 N1 and 27 N2). In multivariate analyses, high tumor cell PDGF-A expression (P = 0.017) correlated with LNM. Tumor cell co-expression of VEGFR-3 and PDGF-B correlated with nodal metastasis and was an independent indicator of poor prognosis (hazard ratio 4.8, confidence interval 95% 2.80-8.31, P < 0.001).
introduction
Lymph node metastasis (LNM) is an early event in metastatic disease and useful for the staging of cancer in the clinic. Initially, two members of the vascular endothelial growth factor (VEGF) family, VEGF-C and VEGF-D, were considered the only lymphangiogenic factors, acting via stimulation of VEGFR-3 expressed on lymphatic endothelial cells [1] . However, a range of lymphangiogenic factors produced by tumor cells, endothelial cells and stromal cells have recently been identified [2] . These include VEGF-A, fibroblast growth factor-2 and members of the insulin-like growth factor (IGF)-1 and -2 and angiopoietin (Ang-1, Ang-2) families. Additionally, interesting preclinical studies have indicated that the plateletderived growth factors (PDGFs) and platelet-derived growth factor receptors (PDGFRs) not only promote hemangiogenesis and direct tumor cell growth but are important players also in lymphangiogenesis [2] .
The PDGF family consists of five isoforms, -AA, -AB, -BB, -CC and -DD, often named PDGF-A (AA), PDGF-B (AB and BB), PDGF-C (CC) and PDGF-D (DD). These ligands bind to tyrosine kinase PDGFR-a and/or -b. The PDGF-AA, -AB, -BB and -CC dimers bind to the a receptor with high affinity, whereas PDGF-BB binds preferentially to the b receptor and PDGF-DD activates b receptor [3] [4] [5] [6] .
In mouse cornea, PDGF-A and PDGF-B stimulate lymphatic vessel growth, PDGF-B being the most potent [7] . It is possible that PDGF-B-induced lymphangiogenesis is indirectly mediated by activation of the VEGF-C/VEGF-D-and VEGFR-3-signaling pathway [8] , but a study by Cao et al. [7] showed that PDGF-B appears to have a more direct lymphangiogenic effect through PDGFR-a and -b stimulation in the lymphatic endothelial cells. As lymphangiogenesis is a complex process controlled by multiple factors produced by various cell types, the functional outcome might depend on the combined effect of these factors [2] . One may also argue that metastatic spread to lymph nodes can occur in the absence of lymphangiogenesis, presumably via preexisting lymphatic vessels [9] . Moreover, in animal tumor models, it has been observed that lymphangiogenesis was induced in the sentinel nodes even before tumor cells arrive in the nodes, presumably promoted by lymphangiogenic growth factors derived from the primary tumor [10] [11] [12] [13] . Consequently, one may ask whether lymphangiogenesis in the primary tumor is needed for regional metastatic spread. We have previously in this same study cohort found VEGFR-3 to strongly correlate with N2 status and reported both VEGFR-3 and PDGF-B to be independent prognostic factors in non-small-cell lung cancer (NSCLC) patients [14] [15] [16] .
Based on our own previous results as well as relevant preclinical data [7, 8, [14] [15] [16] , our aim is to investigate (i) the correlation between tumor cell and stromal PDGFs/PDGFRs expression with LNM and (ii) the prognostic impact of the coexpression of tumor cell VEGFR-3 and PDGF-B and its association with LNM.
patients and methods

patients and clinical samples
Primary tumor tissues from anonymized patients diagnosed with NSCLC pathologic stage I-IIIA at the University Hospital of Northern Norway (UNN) and Nordland Central Hospital (NLCH) from 1990 through 2004 were used in this retrospective study. In total, 371 patients were registered from the hospital database. Of these, 36 patients were excluded from the study due to the following: (i) radiotherapy or chemotherapy before surgery (n = 10); (ii) other malignancy within 5 years before NSCLC diagnosis (n = 13) and (iii) inadequate paraffin-embedded fixed tissue blocks (n = 13). Adjuvant chemotherapy was not introduced in Norway during this period (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) . Thus, 335 patients with complete medical records and adequate paraffin-embedded tissue blocks were eligible.
This report includes follow-up data as of 30 September 2005. The median follow-up was 96 (range 10-179) months. Complete demographic and clinical data were collected retrospectively. Formalin-fixed and paraffinembedded tumor specimens were obtained from the archives of the Departments of Pathology at UNN and NLCH. The tumors were staged according to the International Union Against Cancer's tumour-nodemetastasis classification and histologically subtyped and graded according to the World Health Organization guidelines [17] . Regarding N status, ipsilateral peribronchial or hilar nodes and intrapulmonary nodes are defined as N1, while N2 includes ipsilateral mediastinal or subcarinal nodes. The National Data Inspection Board and the Regional Committee for Research Ethics approved the study.
microarray construction
All lung cancer cases were histologically reviewed by two pathologists (SA-S and KA-S) and the most representative areas of viable tumor cells (neoplastic epithelial cells) and central tumor stroma were carefully selected and marked on the hematoxylin and eosin slide and sampled for the tissue microarray (TMA) blocks. The TMAs were assembled using a tissuearraying instrument (Beecher Instruments, Silver Springs, MD). The detailed methodology has been previously reported [14] . Briefly, we used a 0.6-mm-diameter stylet, and the study specimens were routinely sampled with two replicate core samples (different areas) of neoplastic tissue and two of tumor stroma. Both normal lung tissue localized distant from the primary tumor and one slide with normal lung tissue samples from 20 patients without a cancer diagnosis were used as negative controls.
To include all core samples, eight tissue array blocks were constructed. Multiple 5-lm sections were cut with a Micron microtome (HM355S) and stained by specific antibodies for immunohistochemistry (IHC) analysis.
immunohistochemistry
The applied antibodies were subjected to in-house validation by the manufacturer for IHC analysis on paraffin-embedded material. The antibodies used in the study were as follows: PDGF-AA (goat polyclonal; AB-221-NA; R&D Systems, Abington, UK; 1 : 200), PDGF-AB/BB (rabbit polyclonal; RB-9257; Neomarkers, Cheshire, UK; 1 : 15), PDGF-CC (goat polyclonal; GT15151; Neuromics, Herford, Germany; 1 : 80), PDGF-DD (goat polyclonal; AF1159; R&D Systems; 1 : 400), PDGFR-a (rabbit polyclonal; RB-9027; Neomarkers; 1 : 75), PDGFR-b (rabbit polyclonal; RB-9032; Neomarkers; 1 : 25) and VEGFR-3 (rabbit polyclonal; Sc-321; Santa Cruz Biotechnology, Santa Cruz, CA; 1 : 10). The IHC procedures for these markers are previously described [14, 16] .
D2-40 (mouse monoclonal; Dako; M3619; 1 : 25) was stained using Ventana Benchmark XT (Ventana Medical Systems Inc.), by using the procedure ultraview DABÒ. Antigen retrieval was done automatically by CC1 mild (30 min). For each antibody, including negative staining controls; all TMA stainings were done in a single experiment.
scoring of IHC
By light microscopy, representative and viable tissue sections were scored semiquantitatively for cytoplasmic staining. The dominant staining intensity in both tumor cells and stromal cells was scored as follows: 0 = negative; 1 = weak; 2 = intermediate and 3 = strong ( Figure 1 ). The cell density of the stroma was scored as follows: 1 = low density; 2 = intermediate density and 3 = high density ( Figure 1 ). All samples were anonymized and independently scored by two pathologists (SA-S and KA-S). In case of disagreement, the slides were reexamined and a consensus was reached by the observers. In most tumor cores as well as in some stromal cores, there is a mixture of stromal cells and tumor cells. However, by morphological criteria, we have only scored staining intensity of tumor cells in tumor cores and intensity and density of stromal cells in stromal cores. When assessing a variable for a given core, the observers were blinded to the scores of the other variables and to outcome. The interobserver scoring agreement has previously been found valid in the same TMA blocks for one ligand and one receptor with similar cytoplasmic staining [14] . After categorizing into high-and low-expression group, the percentage discordance among the pathologists was tumor cell ligand 8%, stromal ligand 8%, tumor cell receptor 2% and stromal receptor 4%. Mean score for duplicate cores from each individual was calculated separately in tumor cells and stroma. High expression in tumor cells was defined as score ‡1.5 (PDGF-C), ‡2 (PDGF-A, PDGFR-a and PDGFR-b), >2 (VEGFR-3) or =3 (PDGF-B and PDGF-D). Stromal expression was calculated by summarizing density score (1-3) and intensity score (0-3) before categorizing into low and high expression. High expression in stroma was defined as score ‡2.5 (PDGFR-b), ‡4 (PDGF-B and VEGFR-3), ‡4.5 (PDGF-A, PDGF-C and PDGFR-a) or ‡5.5 (PDGF-D) [14, 16] .
lymphatic vessel density
We assessed lymphatic vessel density (LVD) by D2-40 immunohistochemical staining and any stained endothelial cell or endothelial cell cluster separated from other stromal elements was considered as single countable microvessel. The LVD was defined as the number of microvessels identified within one array core (0.6 mm diameter): tumor or stromal LVD was scored as 0, negative; 1, one vessel per core; 2, two to five vessels per core; 3, more than five vessels per core. In tumor cores, only microvessels surrounded by viable tumor cells were counted, whereas in stromal cores, only microvessels adjacent to other stromal cells were scored. Mean score for duplicate cores from each individual was calculated separately in tumor cells and stroma. High LVD in tumor and stromal cores was defined as a mean score ‡2.
statistical methods
All statistical analyses were done using the statistical package SPSS (SPSS inc., Chicago, IL), version 15. The chi-square test and Fisher's exact test were used to examine the association between molecular marker expression and various clinicopathological parameters. Univariate analysis was done by using the Kaplan-Meier method, and statistical significance between survival curves was assessed by the log-rank test. Disease-specific survival (DSS) was determined from the date of surgery to the time of lung cancer death. Regarding the independent impact of various pretreatment variables with respect to LNM, multivariate analysis was carried out using binary logistic regression. To assess the independent value of different pretreatment variables on survival, in the presence of other variables, multivariate analysis was carried out using the Cox proportional hazards model. Only variables of significant value from the univariate analysis were entered into the Cox regression analysis. Probability for stepwise entry and removal was set at 0.05 and 0.10, respectively. The significance level used was P <0.05.
results clinicopathological variables
Demographic, clinical and histopathological variables are shown in Table 1 . The median age was 67 (range 28-85) years and the majority of patients were male (76%). The NSCLC tumors comprised 191 squamous cell carcinomas, 95 adenocarcinomas, 31 large-cell carcinomas and 18 bronchioalveolar carcinomas. Due to nodal metastasis or nonradical surgical margins, 59 (18%) patients received postoperative radiotherapy.
univariate analysis
In univariate analysis, the clinical variables age (P = 0.035), gender (P = 0.033), histological subgroup (P = 0.039), differentiation (P < 0.001) and vascular infiltration (P = 0.004) correlated with nodal metastasis (N0 versus N1 versus N2; Table 1 ). In addition, high tumor cell expression of PDGF-A (P = 0.009) and low stromal expression of PDGFR-B (P = 0.037) and PDGF-b (P = 0.048) correlated with LNM (Table 2) .
When examining N0 versus N+ (N1 + N2), tumor cell PDGF-A expression was significantly associated with N+ status (P = 0.003; Table 2 ). Furthermore, low stromal expression of PDGF-B (P = 0.014), PDGF-D (P = 0.016), PDGFR-b (P = 0.019) and D2-40 (P = 0.022) correlated with N+ status. High tumor cell PDGFR-a expression correlated with N2 status (P = 0.017).
There was no significant association between tumor cell (P = 0.92) or stromal (P = 0.99) D2-40 expression and DSS.
multivariate analysis LNM (binary logistic regression)
In the multivariate analysis (Table 3) , including all statistically significant clinicopathological and angiogenic variables from the univariate analysis, high tumor cell expression of PDGF-A (P = 0.017) and poor differentiation (P < 0.001) correlated with node-positive patients (N0 versus N1 + N2). Vascular infiltration (P = 0.001) and age £65 years (P = 0.020) correlated with N2 positivity (N0 + N1 versus N2).
co-expression of PDGF-B/VEGFR-3 and LNM
High PDGF-B/high VEGFR-3 expression was seen significantly (P = 0.003) more often in N+ (47%) than N0 when compared with low PDGF-B/high VEGFR-3 (38%), high PDGF-B/low VEGFR-3 (32%) or low PDGF-B/low VEGFR-3 (25%).
High PDGF-B/high VEGFR-3 expression was seen significantly (P < 0.001) more frequent in N2 (23%) than in N0 + N1 when compared with low PDGF-B/high VEGFR-3 (16%), high PDGF-B/low VEGFR-3 (0%) or low PDGF-B/low VEGFR-3 (3%).
co-expression of PDGF-B/VEGFR-3 and DSS
In univariate analyses, the co-expression of high PDGF-B/high VEGFR-3 was clearly associated with poor survival (P < 0.001), as shown in Figure 2A . The median survival in the high PDGF-B/high VEGFR-3 group was 12.4 months, compared with 57.0 months in the low PDGF-B/high VEGFR-3 group, and was not reached for the high PDGF-B/low VEGFR-3 and low PDGF-B/ low VEGFR-3 expression groups. The 5-year survival rates were 30%, 50%, 64% and 65%, respectively.
In the N+ (N1 + N2) patient cohort (102 patients), the high PDGF-B/high VEGFR-3 expression group (n = 14) had a median survival of 6.5 months and was associated with a significantly worse prognosis (P < 0.001) when compared with the other subgroups ( Figure 2B ). Table 4 shows the co-expression according to pathological stage. In stage IB, II and IIIA, the co-expression of high PDGF-B/high VEGFR-3 is a highly significant predictor of poor prognosis.
The co-expression of PDGF-B/VEGFR-3 is a significant prognostic factor in both postoperative radiation-treated (PORT) (P < 0.001) and non-PORT (P = 0.011) NSCLC Annals of Oncology original article patients. In the PORT group, median DSS was 7.3 months in the high PDGF-B/high VEGFR-3 expression group (n = 25), 47 months in the low PDGF-B/high VEGFR-3 and high PDGF/low VEGFR-3 group (n = 24) and not reached in the low PDGF-B/ low VEGFR-3 expression group (n = 10). The 5-year survival rates were 10%, 37% and 60%, respectively.
In the multivariate Cox proportional hazards analysis, including all significant clinicopathological variables (Table 1) and the co-expression of PDGF-B/VEGFR-3 (total cohort) from the univariate analyses, the co-expression emerged as the most powerful independent prognostic factor [hazard ratio (HR) 4.83, confidence interval 95% 2.80-8.32; Table 5 ]. Tumor status, nodal status, performance status, vascular infiltration and tumor differentiation also emerged as independent prognosticators for DSS.
discussion
We present a large-scale study in an unselected population of surgically resected NSCLC patients using high-throughput TMA. We found tumor cell PDGF-A expression to be independently associated with regional nodal metastasis and the co-expression of PDGF-B and VEGFR-3 in tumor cells to be strongly associated with poor survival.
To our knowledge, this is the first study on the association between PDGF-A expression and lymphatic spread in NSCLC patients. Due to the somewhat surprising finding that high tumor cell PDGF-A expression did not appear to be a prognostic factor in the same cohort [16] , one may speculate whether PDGF-A-induced LNM is less aggressive than LNM induced by other pathways. In an extensive work by Cao [8] , (26) 14 (7) 69 (33) High 125 (37) 92 (7) 21 (17) 12 (9) 33 (26 Annals of Oncology original article after implanting PDGF-A and PDGF-B in mouse cornea, they observed that both factors induced growth of lymphatic vessels, though PDGF-B was more potent than PDGF-A. Additionally, its main receptor, PDGFR-a, together with PDGFR-beta was detected on the induced lymphatic endothelial cells. In our clinical lung cancer cohort, expression of tumor cell PDGFR-a correlated with N2 status in univariate analyses, indicating a possible autocrine loop in the tumor cells. The fact that tumor cell PDGF-A expression is an independent predictor of nodal metastasis may be explained by a paracrine function where PDGFR-a-expressing lymphatic endothelial cells are stimulated. Corroborating our findings, Shikada et al. [18] , using cell lines and surgical specimens of human NSCLCs, demonstrated PDGF-A to be an essential autocrine stimulator of VEGF-A expression. Although VEGF-A was characterized primarily according to angiogenesis, it has lately been associated also to lymphangiogenesis and LNM [1, 15] . Whether tumor cell PDGF-A as a predictor of LNM is explained by a direct PDGF-A/PDGFR-a stimulation or by an increased VEGF-A production needs to be further elucidated. We have earlier shown tumor cell PDGF-B to be an independent prognosticator for survival [16] . Herein, tumor cell PDGF-B was not associated with LNM. As PDGF-B is considered a direct lymphangiogenic factor and has been reported as a more potent inducer of lymphangiogenesis than PDGF-A [7] , PDGF-B's lacking association with LNM was somewhat surprising. However, it may be possible that PDGF-B-induced lymphangiogenesis in some cancer types is indirectly mediated by activation of the VEGF-C/VEGF-D/VEGFR-3 pathway [8] . We know that PDGF-B may be important also in angiogenesis and a direct stimulator of tumor cell growth, which may explain its prognostic impact [8] .
As previously reported in this study cohort, tumor cell VEGFR-3 is strongly associated with N2 status and proven as an independent prognostic factor [15] . Interestingly, the coexpression of tumor cell PDGF-B and VEGFR-3 appears herein to be significantly associated with LNM and to have a profound prognostic impact. In two previous publications, separate Cox regression analyses showed that high tumor cell expression of VEGFR-3 and PDGF-B resulted in respective HRs of 1.7 and 2.1 [14, 16] . Herein, the co-expressions of high PDGF-B and high VEGFR-3 gave an HR of 4.8, indicating an at least additive effect.
From a clinical point of view, it is appealing separately to study lymph node-positive patients (N+) with respect to outcome. Though the number of patients (14 of 102) with high Percentage based on total number in each expression level. NSCLC, non-small-cell lung cancer; PDGFs, platelet-derived growth factors; PDGFRs, platelet-derived growth factor receptors. PDGF-B and high VEGFR-3 expression was limited, these patients had a miserable prognosis with a median survival of only 6.5 months. This finding indicates that mechanisms beyond lymphangiogenesis and regional metastases may be plausible. In a recent publication, Tammela et al. [19] stated that angiogenic sprouting is impaired without VEGFR-3 signaling. Within the N+ group though, there is a significantly better prognosis among patients without the co-expression of VEGFR-3/PDGF-B. Hence, one may speculate whether LNM are biologically less aggressive without activation of both the PDGF-B and VEGFR-3 pathway. This is also of interest regarding the patients who received postoperative radiotherapy. We have previously reported tumor cell PDGF-B expression to be an independent prognostic factor in this patient group [20] , but the co-expression data presented herein indicate a larger impact on survival. While antiangiogenic treatment targeting the VEGF/VEGFR axis is established for several cancer types as colorectal and breast cancer [21] , several new tyrosine kinase inhibitors targeting both the VEGF and PDGF axis are under evaluation in current clinical trials [21] . For instance, sorafenib, targeting both VEGFR-3 and PDGFR-b, is now in clinical use for renal cell carcinomas [22] . To our knowledge, we are the first to detect such a substantial prognostic impact by the co-expression of VEGFR-3 and PDGF-B. New prospective studies are needed to elucidate whether this co-expression also may be predictive for antiangiogenic treatment. Based on our results, such targeted therapy could be beneficial especially in stage IB-IIIA patients or those requiring postoperative radiotherapy. In our TMA blocks, there were no significant independent associations between stromal or tumor core LVD and DSS or LNM. This contrasts some previous NSCLC studies [23] [24] [25] [26] . To our knowledge, this is the first TMA study to evaluate LVD. Podoplanin, recognized by the monoclonal D2-40 antibody, is considered the most reliable marker for lymphatic endothelial cells [1] . Herein, we have mainly assessed the intratumoral LVD. Accordingly, intratumoral lymphatic vessels have been found vital for lymphatic metastasis [27] [28] [29] , whereas some studies have shown that the density of lymphatic vessels located immediately adjacent to the tumor is associated with the presence of LNM [30] [31] [32] [33] . Several pitfalls may explain why LVD did not predict LNM or DSS, herein. There is no consensus for LVD assessments in TMA blocks. Whether the TMA technique is unsuitable for evaluating LVD, and conventional section analysis is a prerequisite to obtain a representative LVD measure, is still an open question.
In conclusion, we find tumor cell PDGF-A expression to be an independent predictor of LNM. The co-expression of high PDGF-B/high VEGFR-3 in tumor cells is significantly Figure. 2. Disease-specific survival curves according to tumor cell coexpression of vascular endothelial growth factor receptor-3 (VEGFR-3) and platelet-derived growth factor-B (PDGF-B) (A) in the total cohort of patients (n = 335) and (B) in all patients with N + status (n = 102). High PDGF-B/high VEGFR-3 7 6.5 0 PDGF, platelet-derived growth factor; VEGFR, vascular endothelial growth factor receptor; DSS, disease-specific survival; NR, not reached.
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associated with LNM and a poor prognosis. In patients with nodal metastasis, high PDGF-B/high VEGFR-3 co-expression led to a profoundly detrimental prognosis. As a consequence, inhibiting both the PDGF-B and VEGFR-3 axis seems to be an appealing approach in NSCLC treatment.
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